NCT05278975View on ClinicalTrials.gov

Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

186

Participants

Timeline

Start Date

March 31, 2022

Primary Completion Date

April 1, 2025

Study Completion Date

April 1, 2025

Conditions
Malignant Pleural EffusionMalignant Pleural MesotheliomaMesotheliomaMesotheliomas PleuralMesothelioma; LungPleural Effusion, Malignant
Interventions
DRUG

RSO-021

A naturally-occurring, sulfur-rich, cyclic oligopeptide antibiotic of the thiopeptide class.

Trial Locations (10)

BS105NB

RECRUITING

South Mead North Bristol Hopsital, Bristol

Unknown

RECRUITING

NHS Greater Glasgow & Clyde, Glasgow

LS970F

RECRUITING

Leeds Teaching Hospital, Leeds

LE1 5WW

RECRUITING

Facility: HOPE Clinical Trials Facility, Leicester Royal Infirmary, Leicester

EC1A7BE

RECRUITING

Barts Health NHS Cancer Institute, London

SE19RT

RECRUITING

Guys and St Thomas NHS Foundation Trust, London

SW3 6JJ

RECRUITING

The Royal Marsden, London

M204BX

RECRUITING

The Christie NHS, Manchester

NE29 8NH

RECRUITING

Northumbria NorthTyne Side General Hospital, North Shields

OX42PG

RECRUITING

Oxford University Hospitals NHS Foundation, Oxford

All Listed Sponsors
lead

RS Oncology LLC

INDUSTRY